A possible role of vitamin D in the treatment of COVID-19 disease

Ana Maria Alexandra STANESCU1, Anca Angela SIMIONESCU2,3, Ioana Veronica GRAJDEANU1, Mira FLOREA4

1 Department of Family Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2 Filantropia Clinical Hospital, Bucharest, Romania
3 Department of Obstetrics and Gynecology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
4 Department of Family Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

Abstract
Vitamin D has antimicrobial and immunomodulatory activities playing an essential role as an adjuvant treatment to reduce the incidence and severity of various conditions, including influenza and recurrent respiratory infections. Vitamin D insufficiency and deficiency are reported by many countries, especially in the elderly population, requiring intervention by vitamin D supplementation even before the onset of the COVID-19 pandemic. From the beginning of the pandemic, it was considered that vitamin D has a role in preventing and treating COVID-19. The few available studies show a perspective of vitamin D therapy in preventing and early treatment of SARS-CoV-2 infection.

Keywords: vitamin D, COVID-19, treatment

INTRODUCTION
An unprecedented threat is a COVID-19 pandemic. More than 1.7 million people died from SARS-CoV-2 infections by December 2020 (1). Therapeutic options are still limited, and intensive care units’ capacity is often exceeded due to a large number of patients. The population’s active vaccination campaign is an option, but the effectiveness will be visible over time.

Vitamin D has antimicrobial and immunomodulatory activities playing an essential role as an adjuvant treatment to reduce the incidence and severity of various conditions, including influenza and recurrent respiratory infections (2). A low level of vitamin D predisposes to an increased risk of developing respiratory infections (3). The antimicrobial action of vitamin D depends on activating the innate and adaptive immune response, facilitating the infectious agent’s elimination. At the molecular level, vitamin D promotes monocytes’ differentiation into macrophages, improves chemotaxis, leukocyte recruitment, and antimicrobial activity of innate immune system cells (4). The immunomodulatory role of vitamin D is complex; in particular, it reduces immunoglobulin production, the T-helper 1 and T-helper 17 response, decreases the release of pro-inflammatory cytokines, and promotes the proliferation of regulatory T cells and the development of a T-helper response 2 (5,6).

Vitamin D insufficiency and deficiency are reported in many countries, especially in the elderly population, requiring intervention by vitamin D supplementation...
even before the onset of the COVID-19 pandemic (7). Large-scale supplementation of vitamin D, especially for the elderly and high-risk groups, seems to be necessary even in the absence of the COVID-19 pandemic, being recommended and practised in some countries (8).

Since the beginning of the SARS-CoV-2 pandemic, it was considered that vitamin D has a role in preventing and treating COVID-19 (9). Its broad-spectrum immunomodulatory action allows the hypothesis of the usefulness of vitamin D supplementation in COVID-19 to prevent progression to severe manifestations of the disease and to reduce the transmission of the infectious agent. However, few studies support this hypothesis, especially given the short time since the pandemic’s onset. However, vitamin D should be considered an affordable, viable variant with reduced side effects in preventing or early treatment of SARS-CoV-2 infection (Figure 1).

Prevention of COVID-19 may be suggested in using the supplement in Table 1, individualized given the patient’s risk factor and initial 25-OHD levels. The beneficial effect of high-dose administration of vitamin D for a short period of time in respiratory infections could not be highlighted (3).

**VITAMIN D SUPPLEMENTATION TO PREVENT SARS-COV-2 INFECTION**

Merzon et al. conducted a study on 7,807 people between February 1 and April 30, 2020, following the COVID-19 positive ratio with the value of vitamin D, this ratio is 1.45 (p < 0.001); Low levels of vitamin D (< 30 ng/ml) were reported in 85% of the population tested (10).

Hastie et al. conducted a study in the United Kingdom on a group of 349,598 people between March 16, 2020 and April 14, 2020; they reported an inversely proportional association between vitamin D levels and the risk of COVID-19 infection, this association did not persist after covariate adjustment (11). It is important to note that this study used vitamin D levels measured between 2006 and 2010 and maybe weak indicators of vitamin D levels in 2020.

In the United States, a dose-response relationship was followed in a cohort of > 190,000 patients, a proportional inverse relationship was observed between circulating levels of 25(OH)D and SARS-CoV-2 positivity, with a positive rate of 54%, higher in those who had a circulating level of 25(OH)D < 20 ng/ml compared to those who had a blood level of 30-34 ng/ml in the multivariable analysis (12).

Another case-control study in 201 hospitalized patients and 201 appropriate controls reported the inverse association between vitamin D levels and COVID-19 infection (13).

**TABLE 1. Recommended doses of vitamin D (2,3,14)**

| Supplementation | Dose |
|-----------------|------|
| Vitamin D       | 400–1200 IU daily for 6–12 months |
| In patients with vitamin D deficiency or insufficiency, consider higher doses |

**VITAMIN D SUPPLEMENTATION TO PREVENT THE SEVERITY AND / OR MORTALITY OF COVID-19**

Castillo et al. conducted a randomized study of 76 hospitalized patients with COVID-19 with radiologically confirmed acute respiratory infection who received standard therapy, including a combination of hydroxychloroquine and azithromycin. On the day of admission, eligible patients received 25-hydroxyvitamin D 3 at random, 0.532 mg = 21,280 IU. These selected patients received oral calcifediol (0.266 mg = 10.640 IU) on days 3 and 7, then weekly until discharge or hospitalization in the intensive care unit. Only 1 in 50 patients treated with calcifediol versus 13 in 26 who did not receive calcifediol treatment required intensive care admission (15).

In Germany, a cohort study of 185 patients showed an 80% decrease in the risk of invasive mechanical lethargy or death and a 90% decrease in mortality in patients with sufficient vitamin D levels than patients with vitamin D deficiency (16).

In a cohort study on 30 patients, Vassiliou et al. had observed an increase in mortality in patients with low vitamin D levels (17). In France, the risk of severe disease progression and death within 14 days of hospitalization was over 90% lower among patients who were regularly supplemented with vitamin D in the previous year compared to patients without a supplement of vitamin D (18).

In the United Kingdom, a study was reported in 986 hospitalized participants with COVID-19 and vitamin D
therapy; in the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a strongly reduced risk of mortality COVID-19; this finding was replicated in a validation cohort of 541 patients (19).

Rastogi et al. supplemented with high doses of cholecalciferol (60,000 IU daily for at least seven days) in asymptomatic or vitamin D deficient RNA-positive SARS-CoV-2 patients, SARS-CoV-2 viral clearance improved, and levels increased other inflammatory markers (20).

In Brazil, a multicenter, double-blind, randomized, placebo-controlled study of 240 hospitalized patients with severe COVID-19 showed that a single dose of 200,000 IU of vitamin D3 was also safe and effective in increasing the level of 25-hydroxyvitamin D but did not significantly reduce the duration of hospitalization or any other clinically relevant outcomes compared to placebo (21).

**CONCLUSIONS**

Given the potential immunomodulatory effects of vitamin D supplementation, it may help prevent respiratory infections and complications. The few available studies show a perspective of vitamin D therapy in preventing and early treatment of SARS-CoV-2 infection. Several ongoing studies and other future studies will help determine the effects of vitamin D supplementation on COVID-19 and determine the ideal dose.

---

**REFERENCES**

1. Johns Hopkins University Corona Virus Resource Center. Available at: https://covid19.jhu.edu/.
2. Martineau AR, Jolliffe DA, Greenberg L, et al. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. *Health Technol Assess.* 2019;23(2):1-44.
3. Pecora F, Persico F, Argentiero A, et al. The Role of Micronutrients in Support of the Immune Response against Viral Infections. *Nutrients.* 2020;20;12(10):3198.
4. Costagliola G, Spada E, Comberiati P, Peroni DG. Could nutritional supplements act as therapeutic adjuvants in COVID-19? *Ital J Pediatr.* 2021;47(1):32.
5. Dankers W, Colin EM, van Hamburg JP. Lubberts E. Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential. *Front Immunol.* 2016;7:679.
6. Hewison M. Vitamin D and immune function: an overview. *Proc Nutr Soc.* 2012;71(1):50-61.
7. Cashman KD, Dowling KW, Škrabáková Z, et al. Vitamin D deficiency in Europe: molecular mechanisms and therapeutic potential. *Front Immunol.* 2016;14:258.
8. Rizzoli R, Boonen S, Brandi ML, et al. Vitamin D supplementation in elderly or postmenopausal women: A 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Curr Med Res Opin.* 2013;29:305-313.
9. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients.* 2020;12:988.
10. Merzon E, Tworowski D, Gorohovski A, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: An Israeli population-based study. *FEBS J.* 2020;287:3693-3702.
11. Hastie CE, Mackay DF, Ho F, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. *Diabetes Metab Syndr.* 2020;14:561-565.
12. Kaufman HW, Niles JK, Kroll MH, et al. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. *PLoS One.* 2020;15:e0239252.
13. Abdollahi A, Sarvestani HK, Rafat Z, et al. The Association Between the Level of Serum 25(OH) Vitamin D, Obesity, and underlying Diseases with the risk of Developing COVID-19 Infection: A case-control study of hospitalized patients in Tehran, Iran. *Int J Vitam Nutr Res.* 2020.
14. Legitimo A, Bertini V, Costagliola G, et al. Vitamin D status and the immune assessment in 22q11.2 deletion syndrome. *Clin Exp Immunol.* 2020;200(3):272-286.
15. Castillo ME, Costa LME, Barrios JMV, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. *J Steroid Biochem Mol Biol.* 2020;203:105751.
16. Radujkovic A, Hippchen T, Tiwari-Heckler S, et al. Vitamin D Deficiency and Outcome of COVID-19 Patients. *Nutrients.* 2020;12:2757.
17. Vassiliou A, Jahaj E, Pratikaki M, et al. Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort. *Nutrients.* 2020;12:E3773.
18. Annweiler G, Corvaisier M, Gautier J, et al. Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study. *Nutrients.* 2020;12:E3377.
19. Ling SF, Broad E, Murphy R, et al. High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study. *Nutrients.* 2020;12:3799.
20. Rastogi A, Bhansali A, Khare N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled, study (SHADE study). *Postgrad Med J.* 2020.
21. Murai IH, Fernandes AL, Sales LP, et al. Effect of Vitamin D3 Supplementation vs. Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial. *medRxiv.* 2020.